Cubist Systematic Strategies LLC Purchases 1,751 Shares of Inogen, Inc $INGN

Cubist Systematic Strategies LLC grew its position in Inogen, Inc (NASDAQ:INGN) by 1.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 124,993 shares of the medical technology company’s stock after purchasing an additional 1,751 shares during the quarter. Cubist Systematic Strategies LLC owned approximately 0.46% of Inogen worth $891,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of INGN. DAFNA Capital Management LLC boosted its stake in Inogen by 119.4% during the first quarter. DAFNA Capital Management LLC now owns 458,065 shares of the medical technology company’s stock worth $3,266,000 after acquiring an additional 249,275 shares in the last quarter. Nuveen LLC bought a new position in Inogen during the first quarter worth $1,097,000. Royce & Associates LP boosted its stake in Inogen by 42.8% during the first quarter. Royce & Associates LP now owns 444,457 shares of the medical technology company’s stock worth $3,169,000 after acquiring an additional 133,258 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Inogen by 25.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company’s stock worth $5,574,000 after acquiring an additional 123,208 shares in the last quarter. Finally, Monaco Asset Management SAM boosted its stake in Inogen by 119.1% during the first quarter. Monaco Asset Management SAM now owns 167,594 shares of the medical technology company’s stock worth $1,195,000 after acquiring an additional 91,094 shares in the last quarter. 89.94% of the stock is owned by institutional investors.

Inogen Price Performance

INGN opened at $8.53 on Wednesday. The company’s 50-day moving average is $7.20 and its 200 day moving average is $7.08. Inogen, Inc has a fifty-two week low of $5.70 and a fifty-two week high of $12.91. The firm has a market capitalization of $230.65 million, a P/E ratio of -8.05 and a beta of 1.78.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Thursday, August 7th. The medical technology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Inogen had a negative net margin of 7.58% and a negative return on equity of 13.77%. The company had revenue of $92.28 million for the quarter, compared to analyst estimates of $90.40 million. Inogen has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts expect that Inogen, Inc will post -1.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on INGN. B. Riley began coverage on shares of Inogen in a research note on Monday, June 16th. They set a “buy” rating and a $14.00 target price on the stock. Needham & Company LLC raised shares of Inogen from a “hold” rating to a “moderate buy” rating and set a $12.00 target price on the stock in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.